Alaleh Nouri Sells 5,363 Shares of PROCEPT BioRobotics (NASDAQ:PRCT) Stock

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) EVP Alaleh Nouri sold 5,363 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $25.96, for a total transaction of $139,223.48. Following the completion of the transaction, the executive vice president owned 105,354 shares of the company’s stock, valued at approximately $2,734,989.84. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alaleh Nouri also recently made the following trade(s):

• On Tuesday, March 17th, Alaleh Nouri sold 304 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $28.15, for a total transaction of $8,557.60.
• On Tuesday, March 10th, Alaleh Nouri sold 3,243 shares of PROCEPT BioRobotics stock. The stock was sold at an average price of $25.65, for a total transaction of $83,182.95.
• On Friday, March 6th, Alaleh Nouri sold 6,892 shares of PROCEPT BioRobotics stock. The shares were sold at an average price of $23.70, for a total transaction of $163,340.40.

PROCEPT BioRobotics Stock Performance

NASDAQ PRCT traded down $0.49 during trading hours on Thursday, hitting $25.68. The company had a trading volume of 987,670 shares, compared to its average volume of 1,680,564. The business has a 50 day moving average of $28.30 and a 200-day moving average of $32.21. The company has a market cap of $1.45 billion, a PE ratio of -15.02 and a beta of 1.02. PROCEPT BioRobotics Corporation has a 1-year low of $19.35 and a 1-year high of $66.85. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). PROCEPT BioRobotics had a negative return on equity of 25.13% and a negative net margin of 31.02%.The firm had revenue of $76.38 million for the quarter, compared to analyst estimates of $93.70 million. During the same quarter last year, the firm posted ($0.35) EPS. The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. As a group, equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PRCT. UBS Group started coverage on PROCEPT BioRobotics in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research report on Thursday, January 22nd. Jefferies Financial Group cut shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 26th. TD Cowen lowered their price objective on shares of PROCEPT BioRobotics from $50.00 to $34.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Piper Sandler dropped their price objective on shares of PROCEPT BioRobotics from $50.00 to $28.00 and set an “overweight” rating on the stock in a research note on Thursday, February 26th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Hold” and a consensus price target of $40.82.

Institutional Investors Weigh In On PROCEPT BioRobotics

Large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd lifted its holdings in shares of PROCEPT BioRobotics by 436.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock worth $29,000 after purchasing an additional 746 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new position in PROCEPT BioRobotics in the 3rd quarter valued at $30,000. Center for Financial Planning Inc. acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at $40,000. Vega Investment Solutions raised its position in PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock worth $45,000 after buying an additional 265 shares during the last quarter. Finally, US Bancorp DE lifted its stake in shares of PROCEPT BioRobotics by 175.7% in the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock worth $60,000 after acquiring an additional 1,079 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.